What was the primary endpoint of IMPROVE-IT?

A five-component composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring hospitalization, coronary revascularization (at least 30 days post-randomization), and nonfatal stroke. The ezetimibe arm hit 32.7% vs 34.7% for simvastatin alone over a median of six years.

How much did ezetimibe lower LDL in IMPROVE-IT?

The median LDL at one year was 53.7 mg/dL in the ezetimibe + simvastatin group compared to 69.5 mg/dL with simvastatin alone. That is roughly a 16 mg/dL additional reduction from ezetimibe.

Did IMPROVE-IT show a mortality benefit?

No. Cardiovascular death was nearly identical between arms (HR 0.99). All-cause mortality also showed no significant difference. The benefit was driven by reductions in myocardial infarction and stroke.

Is ezetimibe safe long-term?

In IMPROVE-IT, six years of ezetimibe use showed no increase in cancer, liver enzyme elevations, myopathy, or gallbladder disease compared to placebo. This is one of the longest safety datasets for any lipid-lowering drug.

Which patients benefited most in IMPROVE-IT?

Patients with diabetes (27% of enrollment) showed a hazard ratio of 0.86 with a 5.5 percentage point absolute reduction. Older patients (75+) also showed numerically larger benefit, though this subgroup was smaller.

How does IMPROVE-IT compare to PCSK9 inhibitor trials?

PCSK9 inhibitors (FOURIER, ODYSSEY OUTCOMES) achieved larger LDL reductions and larger absolute event reductions. However, ezetimibe is generic (under $15/month) while PCSK9 inhibitors cost thousands annually. Guidelines position ezetimibe as the first add-on step before PCSK9 inhibitors.

Did IMPROVE-IT change cholesterol guidelines?

Yes. The 2018 AHA/ACC and 2019 ESC/EAS guidelines both cited IMPROVE-IT as the basis for recommending ezetimibe as first-line non-statin add-on therapy in high-risk patients. The ESC lowered its LDL target for very-high-risk patients to <55 mg/dL partly based on this trial.

Does IMPROVE-IT apply to primary prevention?

Not directly. All enrolled patients had recent acute coronary syndrome. The EWTOPIA 75 trial provides limited primary-prevention data in elderly Japanese patients, but no large Western primary-prevention trial of ezetimibe exists.

What was the NNT in IMPROVE-IT?

Approximately 50 patients treated for seven years to prevent one primary composite event. In the diabetic subgroup, the NNT was closer to 18, reflecting the larger absolute benefit.

Why did it take so long for ezetimibe prescribing to increase?

Cost was the main barrier. Branded ezetimibe was expensive until generic availability in late 2016. Physician perception of a "modest" result and distraction from PCSK9 inhibitor launches also slowed adoption.

What IMPROVE-IT Actually Changes in Clinical Practice

Q: Does IMPROVE-IT apply to primary prevention?

Not directly. All enrolled patients had recent acute coronary syndrome. The EWTOPIA 75 trial provides limited primary-prevention data in elderly Japanese patients, but no large Western primary-prevention trial of ezetimibe exists.

Q: What was the NNT in IMPROVE-IT?

Approximately 50 patients treated for seven years to prevent one primary composite event. In the diabetic subgroup, the NNT was closer to 18, reflecting the larger absolute benefit.

Q: Why did it take so long for ezetimibe prescribing to increase?

Cost was the main barrier. Branded ezetimibe was expensive until generic availability in late 2016. Physician perception of a "modest" result and distraction from PCSK9 inhibitor launches also slowed adoption.

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

| Parameter | Detail | |---|---| | Trial name | IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial) | | N | 18,144 | | Intervention | Ezetimibe 10 mg + simvastatin 40 mg | | Comparator | Placebo + simvastatin 40 mg | | Duration | Median 6 years follow-up | | Primary endpoint | Composite of cardiovascular death, major coronary event, or nonfatal stroke (MACE) | | Key result | 32.7% vs 34.7%, HR 0.936 (95% CI 0.89-0.99, p = 0.016), a 6.4% relative risk reduction |

Why IMPROVE-IT Mattered More Than Its Modest Headline Suggests

A 2% absolute risk reduction does not sound dramatic. But IMPROVE-IT was never really about the size of its hazard ratio. It was about settling a biological question that had stalled lipid pharmacology for a decade: does lowering LDL-C through a non-statin mechanism produce the same event-rate benefit per unit of LDL reduction as a statin does?

The answer was yes. Before this trial reported in 2015, every previous attempt to show non-statin LDL lowering reduced hard endpoints had failed (niacin in AIM-HIGH, CETP inhibitors in dal-OUTCOMES). Ezetimibe works through cholesterol absorption inhibition at the intestinal brush border, a completely different pathway from HMG-CoA reductase inhibition. By confirming benefit through a second mechanism, IMPROVE-IT validated the LDL hypothesis itself, not just statins as a drug class.

Trial Design: Details That Shaped the Result

Enrollment required hospitalization for an acute coronary syndrome (unstable angina, NSTEMI, or STEMI) within the prior 10 days. Patients had to have an LDL-C between 50 and 125 mg/dL if already on lipid therapy, or between 50 and 100 mg/dL if not. This is a critical detail. The trial population started with LDL levels most physicians would have considered acceptable in 2005 when enrollment began.

The median baseline LDL was 93.8 mg/dL in both arms. By one year:

| Group | Median LDL-C at 1 year | |---|---| | Ezetimibe + simvastatin | 53.7 mg/dL | | Placebo + simvastatin | 69.5 mg/dL |

That 16 mg/dL separation persisted over seven years. The absolute event reduction tracked almost exactly with what the Cholesterol Treatment Trialists' (CTT) meta-regression would predict for that degree of LDL lowering, roughly 5-6% relative reduction per 10 mg/dL.

Randomization was stratified by site and prior statin use. Double-blinding was maintained throughout. The trial was event-driven with a target of 5,250 primary endpoints, which is why follow-up stretched to a median of six years. This unusually long observation period turned out to be important: Kaplan-Meier curves separated slowly but steadily, suggesting that the benefit accumulated with duration of exposure rather than appearing as an early spike.

What the Primary Endpoint Actually Showed

The five-component MACE composite at seven years:

| Component | Ezetimibe arm | Simvastatin alone | HR (95% CI) | |---|---|---|---| | Primary composite | 32.7% | 34.7% | 0.936 (0.89-0.99) | | CV death | 6.8% | 6.9% | 0.99 (0.87-1.12) | | Major coronary event | 13.1% | 14.8% | 0.88 (0.81-0.95) | | Nonfatal stroke | 3.4% | 4.1% | 0.83 (0.70-0.99) | | MI | 12.8% | 14.4% | 0.87 (0.80-0.95) | | Coronary revascularization (>30 days) | 21.8% | 23.4% | 0.95 (0.90-1.01) |

Two things stand out. First, the benefit was concentrated in MI and stroke rather than cardiovascular death. Second, there was no mortality signal in either direction, and the safety profile was clean. Cancer rates, hepatotoxicity, myopathy, and gallbladder events were statistically equivalent between arms.

The HealthRX Practice-Change Framework for IMPROVE-IT

We track three vectors when a trial claims practice relevance: (1) did guidelines actually move, (2) did prescribing behavior change, and (3) what happens to the patients the trial excluded?

1. Guidelines That Moved

The 2018 AHA/ACC Cholesterol Guidelines cited IMPROVE-IT as the basis for recommending ezetimibe as first-line add-on therapy when maximally tolerated statins fail to achieve a >50% LDL reduction or when LDL remains above 70 mg/dL in very-high-risk patients. Before IMPROVE-IT, ezetimibe appeared in guidelines only as a weak recommendation with limited outcome data.

The 2019 ESC/EAS Dyslipidaemia Guidelines went further. They dropped the very-high-risk LDL target to <55 mg/dL (from <70) and explicitly positioned ezetimibe as the step between maximally tolerated statins and PCSK9 inhibitors. This created a treatment algorithm that did not exist before IMPROVE-IT reported.

The trial also informed the FDA's 2017 updated labeling for ezetimibe, which for the first time included cardiovascular risk reduction as an indication rather than LDL lowering alone.

2. Prescribing Behavior: Slower Than Expected

Despite guideline endorsement, ezetimibe uptake remained tepid for years after publication. Several factors contributed:

Generic simvastatin was already cheap. Adding ezetimibe (then still branded as Zetia) roughly tripled the monthly cost. This changed sharply when ezetimibe went generic in late 2016 and the combination tablet followed. Current cash price for generic ezetimibe 10 mg is under $15/month at most pharmacies.
Physician inertia around a "modest" result. A 2% absolute reduction requires treating about 50 patients for seven years to prevent one event (NNT ~50). For individual prescribing decisions, this felt underwhelming, even though population-level impact across millions of post-ACS patients is substantial.
PCSK9 inhibitor distraction. Evolocumab (FOURIER) and alirocumab (ODYSSEY OUTCOMES) reported shortly after IMPROVE-IT and grabbed clinical attention with larger LDL reductions. However, their annual cost ($5,000-14,000 even after rebates) limits accessibility. Ezetimibe remains the cost-effective bridge.

Real-world prescription data from IQVIA and similar trackers show ezetimibe dispensing roughly doubled between 2017 and 2023, with the steepest increase after generic availability rather than after guideline publication.

3. Patients the Trial Excluded

IMPROVE-IT enrolled post-ACS patients within 10 days of hospitalization. This leaves several populations where clinicians extrapolate rather than apply direct evidence:

Chronic stable ASCVD without recent ACS. The biological argument (LDL lowering is LDL lowering) is strong, and guidelines extend ezetimibe to all very-high-risk ASCVD patients. But no dedicated RCT of this size covers stable patients alone.
Primary prevention. The EWTOPIA 75 trial in elderly Japanese patients without established CVD showed a significant reduction in composite cardiac events with ezetimibe, though in a much smaller, demographically narrow cohort. Generalizability to Western primary-prevention populations is uncertain.
Patients on high-intensity statins. IMPROVE-IT used simvastatin 40 mg (moderate intensity). Most U.S. post-ACS patients are now prescribed atorvastatin 80 mg or rosuvastatin 20-40 mg. Starting from a lower LDL baseline may compress the absolute benefit further, though the relative benefit per mg/dL reduction should hold.
Statin-intolerant patients. Ezetimibe monotherapy lowers LDL by approximately 18-20%. IMPROVE-IT does not directly address whether monotherapy ezetimibe reduces events, though EWTOPIA 75 provides partial signal.

Subgroup Findings Worth Knowing

Prespecified subgroup analyses from the primary publication revealed two groups with greater-than-average benefit:

Patients with diabetes (27% of enrollment): HR 0.86 (95% CI 0.78-0.94), an absolute reduction of 5.5 percentage points. This finding drove the 2018 AHA/ACC recommendation for ezetimibe specifically in diabetic post-ACS patients with LDL >70 mg/dL on maximally tolerated statins.
Patients aged 75 and older: showed a numerically larger benefit, though the subgroup was small. The result aligns with EWTOPIA 75 and supports continued lipid treatment in older adults, countering the clinical reflex to deprescribe.

Patients with baseline LDL <70 mg/dL still derived benefit from further lowering, reinforcing the absence of a J-curve at these levels.

Limitations the Authors Acknowledged

The IMPROVE-IT investigators were transparent about several constraints. Simvastatin 40 mg is moderate-intensity therapy, and the trial was designed before high-intensity statins became the post-ACS standard. The long enrollment period (2005-2010) meant background medical therapy evolved during the trial. Event rates were lower than projected, requiring extended follow-up and resulting in a study that took nearly a decade to complete. The result, while statistically significant, carried a p-value of 0.016, which some critics considered borderline for a trial of this scale.

There was no significant reduction in cardiovascular mortality or all-cause mortality. Whether a larger LDL separation (achievable with PCSK9 inhibitors) would have produced a mortality benefit remains unanswered by this trial.

What This Means for a Patient Conversation in 2026

For a post-ACS patient already on high-intensity statin with an LDL of 65 mg/dL, IMPROVE-IT supports adding ezetimibe to push LDL into the low 50s or below. The expected incremental benefit is modest for any single patient but the downside is minimal: ezetimibe is generic, well-tolerated, once-daily, and has a safety profile essentially indistinguishable from placebo over six years of randomized data.

For patients who refuse or cannot tolerate statins, ezetimibe is a reasonable but unproven alternative for event reduction as monotherapy. Clinicians should be honest that the IMPROVE-IT evidence base is for combination use, not solo prescribing.

For patients with diabetes and recent ACS, the subgroup data make a stronger case. The absolute risk reduction in diabetic patients was clinically meaningful and the cost of therapy is negligible.

Frequently asked questions

›

References

Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387-2397. PubMed
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the management of blood cholesterol. Circulation. 2019;139(25):e1082-e1143. PubMed
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2020;41(1):111-188. PubMed
Ouchi Y, Sasaki J, Arai H, et al. Ezetimibe lipid-lowering trial on prevention of atherosclerotic cardiovascular disease in 75 or older (EWTOPIA 75). Circulation. 2019;140(12):992-1003. PubMed
FDA label for ezetimibe (Zetia). FDA